title: Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
abstract: BACKGROUND
  IMC-18F1 (icrucumab), a human monoclonal antibody against vascular endothelial growth factor receptor-1 (VEGFR-1), potently inhibits ligand-dependent phosphorylation of VEGFR-1 and downstream signaling, making icrucumab an attractive candidate for antitumor activity.
  
  
  OBJECTIVE
  The primary objective was to determine the safety profile and maximum tolerated dose of icrucumab in patients with advanced solid tumors that were previously unresponsive to standard therapy or for which no standard therapy was available.
  
  
  METHODS
  In this open-label, dose-escalation, Phase 1 study, patients received icrucumab intravenously weekly at 2, 3, 6, and 12 mg/kg (Cohorts 1-4), every other week (q2w) at 15 mg/kg (Cohort 5), or every third week at 20 mg/kg (Cohort 6). Patients received icrucumab until evidence of progressive disease or other withdrawal criteria were met.
  
  
  RESULTS
  Twenty-six patients received icrucumab. The most common adverse events were fatigue, nausea, peripheral edema, anemia, dyspnea, and vomiting. No dose-limiting toxicities (DLTs) were observed in Cohorts 1-5. Two DLTs were observed in Cohort 6 (anemia and hyponatremia), and enrollment was stopped. No patient demonstrated an immunogenic response. Overall, icrucumab exhibited nonlinear pharmacokinetics at doses >6 mg/kg. Six patients (23.1 %) achieved stable disease with median duration of 11.1 weeks (range = 10.3-18.7 weeks); tumor types were thyroid, melanoma, colorectal (3 patients), and small-cell lung cancers.
  
  
  CONCLUSIONS
  Icrucumab was safely administered weekly at doses of 2-12 mg/kg and q2w at a dose of 15 mg/kg with no DLTs. Based on achievement of stable disease, icrucumab has potential for antitumor activity against advanced solid tumors.
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA, lorussop@karmanos.org.
authors.forename: Patricia M
authors.initials: PM
authors.lastname: LoRusso
authors.forename: Smitha
authors.initials: S
authors.lastname: Krishnamurthi
authors.forename: Hagop
authors.initials: H
authors.lastname: Youssoufian
authors.forename: Nancy
authors.initials: N
authors.lastname: Hall
authors.forename: Floyd
authors.initials: F
authors.lastname: Fox
authors.forename: Aruna
authors.initials: A
authors.lastname: Dontabhaktuni
authors.forename: Dmitri
authors.initials: D
authors.lastname: Grebennik
authors.forename: Scot
authors.initials: S
authors.lastname: Remick
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C548516:IMC-18F1; D040281:Vascular Endothelial Growth Factor Receptor-1
references.citation: Blood. 2001 Feb 1;97(3):785-91
references.pmid: 11157498
references.citation: Nat Rev Clin Oncol. 2009 Sep;6(9):507-18
references.pmid: 19636328
references.citation: J Clin Oncol. 2005 Feb 10;23(5):1011-27
references.pmid: 15585754
references.citation: Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11306-11
references.pmid: 22733742
references.citation: Expert Opin Ther Targets. 2012 Jan;16(1):5-13
references.pmid: 22239434
references.citation: Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213
references.pmid: 17324579
references.citation: J Pathol. 1999 Aug;188(4):369-77
references.pmid: 10440746
references.citation: Curr Vasc Pharmacol. 2011 May;9(3):358-80
references.pmid: 20807189
references.citation: Nat Med. 2001 Nov;7(11):1194-201
references.pmid: 11689883
references.citation: Sci Signal. 2009 Feb 24;2(59):re1
references.pmid: 19244214
references.citation: Cancer Res. 2006 Dec 1;66(23):11089-93
references.pmid: 17145848
references.citation: Cancer. 2010 Feb 15;116(4 Suppl):1027-32
references.pmid: 20127948
references.citation: Semin Nephrol. 2010 Nov;30(6):591-601
references.pmid: 21146124
references.citation: Nat Rev Cancer. 2004 Jan;4(1):71-8
references.pmid: 14708027
references.citation: Curr Vasc Pharmacol. 2012 Jul;10(4):479-93
references.pmid: 22272903
references.citation: Exp Cell Res. 2006 Mar 10;312(5):549-60
references.pmid: 16336962
references.citation: Cancer Res. 2005 Apr 15;65(8):3185-92
references.pmid: 15833849
references.citation: Tohoku J Exp Med. 1998 Jul;185(3):173-84
references.pmid: 9823778
references.citation: Oncologist. 2011;16(12):1729-40
references.pmid: 22135123
references.citation: Nat Rev Cancer. 2008 Dec;8(12):942-56
references.pmid: 19029957
references.citation: Blood. 2004 Nov 1;104(9):2893-902
references.pmid: 15238424
references.citation: Cancer Res. 2000 Sep 15;60(18):5117-24
references.pmid: 11016638
references.citation: Clin Cancer Res. 2006 Nov 1;12(21):6573-84
references.pmid: 17085673
references.citation: Cancer Cell. 2002 Oct;2(4):289-300
references.pmid: 12398893
references.citation: Cancer Res. 1998 May 1;58(9):1952-9
references.pmid: 9581838